evidence: AMRIT a good strategy for affordable cancer drugs. The news on "most recent cancer drugs offer few benefits" pictured the need for rationale use of cancer drugs that was already available in affordable cost and stressed on the fact of new cancer drugs approved by USFDA that was available with high prices in India with meager efficacy. This is also true in all government set up in India. All those new cancer drugs approved by USFDA fit their role in mostly in corporate hospital than government institution catering service for the cancer patients. Here a note on AMRIT (affordable medicines and reliable implants for treatment) is to be mentioned. It was for two non communicable diseases namely cancer and cardiovascular system. Under the AMRIT (Affordable Medicines and Reliable Implants for Treatment) programme medicines will be provided at an affordable cost. More than 195 drugs for treatment of cancer are dispensed. For example1, AMRIT will sell anticancer drug ‘Docetaxel 120mg' used for chemotherapy cycle at Rs 888.75 (93 %) for one cycle whereas Maximum retail price of the injection is Rs 13,440. Similarly, another 'Caboplatin 450mg’ sold at Rs 1,316.25 (50%) of its MRP. More than 1.77 lakhs patients have been benefitted2. This has resulted in saving of around Rs 13 crores out of pocket expenditure to the patients (average discount of 69 percent on MRP). The government is planning to open 300 outlets of AMRIT pharmacy in the country with the aim to reduce the expenditure incurred by common patients on treatment of cancer and heart diseases2.